Add event to my calendar
12 November 2012

International conference: The Pharmaceutical Industry and the Fight Against Doping in Sport

Paris, France

French Parliament House: 
Chaban-Delmas Building, Room Victor Hugo
101 rue de l’Université 75007, Paris

Conference's proceedings & conclusion



FIRST SESSION: The Pharmaceutical Industry and WADA: Uniting for Clean Sport


Ms Valérie Fourneyron, Minister of Sports, Youth, Non Formal Education and Voluntary Organisations, France
Ms Gabriella Battaini-Dragoni, Deputy Secretary General, Council of Europe
Mr Getachew Engida, Deputy Director General, UNESCO
Hon. John Fahey, President, World Anti-Doping Agency (WADA)
Dr Jacques Rogge, President, International Olympic Committee (IOC)

Part 1: Societal and economic risks of doping

Mr David Howman, Director General, WADA
Dr Timothy Armstrong, Coordinator Surveillance and Population-based Prevention Unit, World Health Organisation (WHO)
Mr Philippe Lamoureux, Director General, LEEM, and Council Member of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA)

Part 2: Health industry and anti-doping authorities: what is at stake in the cooperation?

Pr Arne Ljungqvist, Vice President, WADA
Mr Philip Thomson, Senior Vice President, Global Communications, GlaxoSmithKline
Mr James C. Greenwood, President and CEO, Biotechnology Industry Organisation (BIO)

Part 3: Health industry and anti-doping authorities: past experiences and lessons learnt

Dr Olivier Rabin, Science Director, WADA
Dr Philippe Van Der Auwera, Global Head of Drug Safety, Roche

Close: The way forward

Hon. John Fahey, President, WADA

SECOND SESSION: Presentation of the operational framework to the parties concerned (public authorities and pharmaceutical firms) to ensure their effective involvement

Round table 1: From the political concept to raising awareness among those involved: what kind of network to build and how to include all the stakeholders?

Moderator: Pr Arne Ljungqvist, Vice President, WADA
Rapporteur: Mr Jean-Pierre Bourely, Head of Office 'Promotion of Health, Protection of Population and Prevention of Doping', French Sports Ministry

Dr Laetitia Bigger, Senior Manager Vaccines Policy, IFPMA
Dr Timothy Armstrong, Coordinator Surveillance and Population-based Prevention Unit, World Health Organisation (WHO)
Mr Andy Parkinson, Chair of the Ad Hoc European Committee for the World Anti-Doping Agency (CAHAMA) and Chief Executive, UK Anti-Doping
Mr Andrew Emmett, Managing Director, Science and Regulatory Affairs, US BIO
Mr Alexander Schischlik, Team-Leader Anti-Doping and Sports Programme, UNESCO

Round table 2: What framework is needed for co-operation between the World Anti-Doping Agency and stakeholders in the health sector? Lessons learnt: from raising awareness to implementation

Moderator: Dr Steve Elliott, Scientific Executive Director, Amgen (Retired)
Rapporteur: Mr Marc de Garidel, Chairman & CEO, Ipsen and Chairman, G5 Group

Ms Barbara Leishman, Head of Safety Science Quality Risk Management, Roche
Ms Melodi McNeil, Director Regulatory Policy and Intelligence, Abbott
Mr Mark Luttmann, WADA Cooperation Coordinator, GlaxoSmithKline
Dr Anne-Marie Duliège, Chief Medical Officer, Affymax
Dr Olivier Rabin, Director Science, WADA

Summary: How to build on the work already done and further develop co-operation through an action programme?

General Rapporteurs:
Mr David Howman, Director General, WADA
Mr Bruno Genevois, President, Agence française de lutte contre le dopage (AFLD)